We may earn money or products from the companies mentioned in this post.
Relizen and Equelle are often compared by people looking for help with hot flashes, but their ingredients and research are different. A familiar marketing phrase such as hormone-free does not make them interchangeable.
This research-based comparison separates label information, clinical findings, and billing terms. It does not report personal product testing or select a treatment for you.
Product details and displayed prices checked November 3, 2026. Verify the current package and checkout terms before purchasing.
Quick Answer: Main Differences and What Remains Uncertain
The biggest difference is the active ingredient. Relizen is built around a pollen extract.
Equelle is built around S-equol, which gut bacteria make from daidzein, a soy isoflavone.
The selected sources reviewed here do not establish that one product outperforms the other in a direct comparison. This article is not an exhaustive search of every trial, so it does not claim that no comparison has ever been conducted.
Each product has its own small set of studies, run in different ways on different groups of women.
Several things stay uncertain:
- Much of the selected research concerns postmenopausal women. Some pollen research includes perimenopause, but its study design still limits conclusions.
- Current formulas may differ from the ones tested.
- Placebo comparisons, study populations, and outcome measures affect how findings should be interpreted.
Use the current package label to verify the formulation and discuss uncertainties with a clinician or pharmacist. Product descriptions and formulations can change.
Side-by-Side Comparison Table
The table summarizes product information and the selected evidence. Manufacturer descriptions are not independent proof of effectiveness.
| Feature | Relizen | Equelle |
|---|---|---|
| Main formulation | Purified flower pollen blend | Soy-derived S-equol |
| Label point to review | Complete pollen preparation and other ingredients | Contains soy; formulation includes calcium |
| Evidence discussed below | Related pollen trials and observational studies | Placebo and active-comparator S-equol trials |
| Perimenopause relevance | A 2022 observational study included peri- and postmenopausal women | The two trials summarized below enrolled postmenopausal women |
| Main interpretation problem | Related preparation versus current product; observational versus controlled evidence | Tested population, dose, formulation, and comparator |
| Personal suitability | Review the actual label, allergies, and medicines with a professional | Review soy warning, medicines, and health history with a professional |
Label sources: Relizen and Equelle. Study references appear below.
Relizen: Ingredients, Research, and Limitations
What the Label Says
Bonafide lists a proprietary purified cytoplasmic blend containing pollen and pistil extract PI-82 and pollen extract GC-FEM. Check the complete current package for ingredient amounts, excipients, and warnings; do not assume the retail formula exactly matches a study preparation.
What the Selected Research Shows
Winther and colleagues’ 2005 trial randomized menopausal women to Femal, a pollen preparation, or placebo. It enrolled 64 women and 54 completed the trial; the abstract reports hot-flash improvements favoring active treatment after three months. This is controlled evidence for the studied preparation, not verification of every feature of current Relizen.
A 2022 multicenter observational study included 108 peri- and postmenopausal women and reported symptom improvements after three months of purified pollen treatment. Its inclusion of perimenopausal women is relevant, but a before-and-after observation does not establish causation or superiority to another product.
Limitations Worth Knowing
Study design, participant selection, formulation, and duration affect how the findings apply to a reader. A small controlled trial and an observational study answer different questions. Neither of the studies summarized here directly compares current Relizen with current Equelle.
Funding and conflict-of-interest details were not established for every source used here. Check the full paper before labeling research independent or manufacturer-funded; an author’s affiliation and a study’s funding are related but distinct facts.
Our Relizen review examines additional study-design and product questions.
Equelle: Ingredients, Research, and Limitations
What the Label Says
Equelle identifies S-equol as its key ingredient and lists fermented soy germ and dicalcium phosphate among its ingredients. Its page says not to use it with soy allergy or sensitivity. Review the full current label rather than relying on the ingredient name alone.
What the Selected Research Shows
A 2012 placebo-controlled trial by Aso and colleagues enrolled 160 equol-nonproducing postmenopausal Japanese women; 126 completed the study. The tested S-equol regimen produced a greater reduction in hot-flash frequency than placebo after 12 weeks. The population and preparation matter: this was not a direct comparison with Relizen or a trial specifically establishing effectiveness of today’s Equelle during perimenopause.
A separate 2012 pilot trial by Jenks and colleagues enrolled 102 postmenopausal women and compared several S-equol doses with soy isoflavones. Hot-flash reductions at week eight were similar across groups; some cumulative and subgroup analyses favored higher S-equol doses. Because this was an active-comparator trial, it does not establish superiority over placebo. Higher-dose findings are not instructions to increase a commercial product’s labeled dose.
The lead author’s listed affiliation was Pharmavite, which is relevant commercial context. That affiliation does not by itself determine the quality of the design or replace checking the paper’s disclosures.
Limitations Worth Knowing
Positive findings in a selected postmenopausal population cannot automatically establish benefit for someone with irregular cycles during perimenopause. Likewise, a result for S-equol is not proof that every formulation containing it has identical effects.
Avoid drawing conclusions from an ingredient’s proposed mechanism alone. A hormone-free marketing claim does not settle effectiveness, interactions, or suitability for a history of hormone-sensitive disease.
Comparing the Evidence Fairly
A fair Relizen vs Equelle comparison cannot be built by lining up percentages from different advertisements. The source, outcome measure, population, and comparator must be considered together.
Three kinds of information
It helps to sort what you read into three piles.
Manufacturer claims come from product pages, ads, and packaging. They describe the company’s positioning and the claims to examine.
Clinical research includes randomized trials and observational studies. Check the design, funding, number of participants, duration, formulation, and relevance to your situation.
Customer testimonials are reviews and social posts. They describe individual experiences, including perceived effects or ordering problems. They cannot establish causation, a treatment effect, or how often an adverse effect occurs. The people who respond may differ from those who do not.
Why percentages can’t be lined up
One trial might count hot flashes per day. Another might use a symptom questionnaire.
A percentage improvement from one can’t be set next to a percentage from the other.
Different lengths, different placebo groups, and different starting symptom levels all change the numbers.
Placebo and perimenopause
In the Aso trial, both the S-equol and placebo groups improved. The meaningful treatment comparison is the difference between groups, not simply improvement from baseline. That principle also applies when assessing pollen studies.
Perimenopause adds another layer. Symptoms come and go with cycle changes.
If you feel better on a supplement, you could be seeing the supplement, the placebo effect, or a natural dip in symptoms.
Studies in women a year or more past their last period don’t map neatly onto someone with irregular cycles.
What the Menopause Society says
The 2023 nonhormone therapy position statement from The North American Menopause Society, now The Menopause Society, did not recommend supplements or herbal remedies for vasomotor symptoms. It also did not recommend soy extracts or equol for that purpose. It identifies evidence-supported hormone and nonhormone options for clinical discussion.
Its patient information on hot flashes describes limited or inconsistent evidence for several supplement approaches. A favorable individual study should not be presented as though it overrides the overall clinical guidance.
These selected study summaries use published abstracts and clinical guidance. This is not a systematic review, and the full funding and conflict disclosures were not available for every source. No medical review by a clinician is claimed.
Safety and Label Differences to Discuss With a Clinician
Suitability depends on the complete formulation and your health history. These are questions for a clinician or pharmacist before purchase, not a conclusion that either product is appropriate for you.
Hormone-free describes the ingredient type. Side effects, interactions, and safety in specific health conditions need their own answers.
Allergens
Equelle’s soy warning should be followed. For Relizen, have the actual pollen preparation and complete label assessed alongside your specific allergy history. Flower pollen extract, bee-collected pollen, propolis, and royal jelly should not be treated as interchangeable ingredients.
A purification claim is not enough to establish that a product is safe for a particular person with allergies.
Medications and conditions to mention
Bring your complete medication and supplement list, including any cancer therapy, thyroid medicines, iron, or anticoagulants. Mention pregnancy, breastfeeding, planned surgery, and relevant medical conditions.
Equelle’s manufacturer flags its calcium-containing formulation as a reason to separate it from iron and thyroid medicines. Ask a pharmacist to confirm the timing for your specific regimen; do not change a prescription schedule on your own. This concern should not be described simply as a soy effect.
If you have a history of breast cancer or are receiving cancer treatment, involve your oncology team. Memorial Sloan Kettering notes that pollen-extract studies in cancer populations are needed to establish safety and effectiveness. Neither a hormone-free claim nor a proposed mechanism substitutes for an individualized assessment.
Supplement quality
The FDA does not approve dietary supplements for safety and effectiveness before marketing. A registered facility is not product approval. If a company claims independent testing, check what was tested and whether a named certification applies to that exact product. Identity or contaminant testing does not establish symptom relief.
Symptoms that need a proper check
Do not assume changing bleeding or new symptoms are explained by perimenopause. ACOG advises discussing abnormal bleeding, including bleeding between periods, after sex, or after menopause. Symptoms that disrupt sleep, work, or mood also warrant clinical discussion rather than repeated supplement purchases.
Pricing, Supply Duration, Shipping, and Subscription Terms
Displayed prices checked November 3, 2026; US dollars before tax. Compare the amount billed with the advertised monthly equivalent:
| Purchase option | Relizen | Equelle |
|---|---|---|
| One-time purchase | $58, plus $5 shipping | $42; confirm shipping |
| Short subscription | $42 billed monthly | $39.90 advertised monthly; one bottle shipped every 4 weeks |
| Longer subscription | $114 quarterly ($38/month advertised) | $111 advertised quarterly; three bottles shipped every 12 weeks |
| Six-month option | $198 semiannually ($33/month advertised) | Not listed in the options reviewed |
| Subscription shipping | Listed as free | Listed as free |
Sources: Relizen and Equelle. Verify the actual supply, renewal date, and payment schedule during checkout.
Equelle’s page uses both monthly or quarterly billing language and four- or twelve-week shipment language. These periods are not identical. Confirm which schedule controls recurring charges rather than assuming twelve equal monthly payments or four quarterly shipments per year.
Check supply duration. Match the tablet count and current label serving to the selected purchase option. Do not assume the quantity initially displayed on a product page applies to every option.
Read cancellation and return terms. Check deadlines, the next billing date, whether discounts renew, and whether opened products qualify for a refund. A larger upfront payment can outweigh a lower advertised monthly equivalent for your budget.
Compare total cost. Include applicable shipping and tax. A cost-per-day calculation is useful only after confirming the supply and labeled serving:
Total checkout cost divided by the verified number of days supplied equals the cost per day for that order.
This is a budgeting calculation, not an instruction to start a product, use it for a set number of months, or continue through adverse effects.
Research-Based Pros and Limitations of Each
Relizen
Potential positives: An identifiable pollen formulation and published controlled and observational research on related preparations make its claims possible to examine.
Limitations: Related preparations are not automatically equivalent to the current product. Some evidence is observational, and available findings do not settle long-term safety or individual suitability. Clinical guidance does not recommend supplements as hot-flash treatments.
Equelle
Potential positives: An identified key ingredient, S-equol, and both placebo-controlled and active-comparator research provide specific evidence to assess.
Limitations: Soy warning and medication-related label cautions need attention. Populations and tested formulations may differ from the reader and the current product. Its research cannot be used to establish superiority over Relizen through unrelated percentages.
Questions to Ask Before Choosing Either Product
Print this section and take it to your next appointment. It works best as a set of notes for the conversation.
Start with the symptom affecting you most. Record hot-flash frequency, severity, sleep disruption, and daily impact as practical. Bring whatever notes you have; do not postpone care to complete a fixed tracking period.
Tell your clinician about any history of breast cancer, blood clots, or other hormone-sensitive conditions. List every medication and supplement you take.
Mention any allergy to soy, pollen, or bee products.
Ask whether prescription non-hormonal options or hormone therapy fit your situation. Ask how long to give a supplement before deciding.
Discuss a reassessment plan and reasons to stop. Study lengths and manufacturer timelines are not universal instructions for a personal trial.
Pick one measure, such as hot flashes per day or sleep quality, and track it the whole time. Read the money-back policy before you order, and decide ahead of time when you will cancel the subscription if you stop.
Tracking tip: Notes can help you and a clinician describe patterns and assess a decision. Even careful tracking cannot prove that a supplement caused a change in symptoms.
FAQs and Balanced Conclusion
Which one is better
The selected evidence does not establish a universal winner or a direct advantage of one over the other. Separate studies with different participants and comparators cannot be treated as a head-to-head test.
Safety alongside hormone therapy
Ask your prescriber before combining them. Compatibility depends on the exact products, medicines, doses, and medical history; this comparison does not evaluate individual combinations.
History of breast cancer
Have your oncology team review the full labels and evidence. A supplement’s marketing category does not establish suitability during or after cancer treatment.
Use in perimenopause
Perimenopausal women were included in the 2022 observational pollen study. That is relevant but does not establish causation. The two S-equol trials summarized here enrolled postmenopausal women. None of these selected studies settles an individual’s likely response during perimenopause.
How long until anything shows up
Studies typically ran several weeks to a few months. Experiences vary widely and no result is guaranteed.
What hormone-free means
It means the ingredient is not a hormone. Side effects and interactions can still happen.
Where to read more
The perimenopause supplement comparison provides broader context. The Relizen review goes further into that product’s evidence and practical questions.
Balanced conclusion
Relizen uses pollen extract and Equelle uses S-equol. Both have small bodies of research that point toward possible benefit for hot flashes in some women.
The selected sources do not establish a direct comparative advantage, and important questions about perimenopause applicability remain.
Current Menopause Society guidance is cautious about supplements in general.
If you decide to try one, the practical steps are simple. Check your allergies, run your medications and health history past a clinician, work out the true daily cost from the actual billing terms, and track your symptoms so you can judge the result honestly.
If symptoms are hurting your sleep, work, or mood, talk with a clinician about options that have stronger evidence behind them.
Medical disclaimer: This article is for educational purposes only and is not medical advice. It does not diagnose, treat, or promise any outcome.
Supplements can affect people differently and may interact with medications or health conditions.
Talk with a qualified healthcare provider before starting any supplement, especially if you are pregnant, breastfeeding, have a hormone-sensitive condition, or take prescription medications.
Sources and Further Reading
- Official Relizen information
- Official Equelle information
- Winther et al., 2005: Femal placebo-controlled trial
- Lello et al., 2022: Peri- and postmenopause observational study
- Aso et al., 2012: S-equol placebo-controlled trial
- Jenks et al., 2012: S-equol active-comparator trial
- 2023 nonhormone therapy position statement
- The Menopause Society: Hot flashes
- FDA: Dietary supplement questions and answers
- Memorial Sloan Kettering: Pollen extract
- ACOG: Bleeding around and after menopause